Hung, Chao-Hung
Healthcare Global Enterprises
3 papers on CoChatORCID 0000-0003-1646-9519
Most cited papers
- Verified
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 746
- Verified
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Sangro, B., Chan, S. L., Kelley, R. K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E. N., Furuse, J., Kang, Y. K., et al. (2024) · Annals of Oncology
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 365
- Verified
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan
Tsai, P.-C., Kuo, H.-T., Hung, C.-H., Tseng, K.-C., Lai, H.-C., Peng, C.-Y., Wang, J.-H., Chen, J.-J., Lee, P.-L., Chien, R.-N., et al. (2023) · Journal of Hepatology
Metabolism, Diabetes, and CancerHepatitis C virus research
Cited by 82
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free